Salud financiera de hoja de balance de Janux Therapeutics

Salud financiera controles de criterios 6/6

Janux Therapeutics tiene un patrimonio de los accionistas total de $344.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $380.4M y $36.1M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$344.03m
Patrimonio	US$344.35m
Total pasivo	US$36.06m
Activos totales	US$380.41m

Actualizaciones recientes sobre salud financiera

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19

Recent updates

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($349.2M) de JANX superan a sus pasivos a corto plazo ($13.0M).

Pasivo a largo plazo: Los activos a corto plazo de JANX ($349.2M) superan a sus pasivos a largo plazo ($23.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: JANX está libre de deudas.

Reducción de la deuda: JANX no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: JANX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: JANX dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 60.2% cada año

Salud financiera de hoja de balance de Janux Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Nasdaq Acknowledges Janux Therapeutics’s Non-Compliance with Listing Rule 5605(b)(1)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Recent updates

Janux Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Consensus EPS estimates upgraded to US$1.43 loss, revenue downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Janux Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $296.497596 million.

Janux Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $296.497596 million.

Janux Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Price target increased by 36% to US$37.34

Now 186% overvalued after recent price rise

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo to Chief Scientific Officer

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Consensus revenue estimates increase by 37%

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 11%

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1A Dose Escalation for Psma-Tractr Janx007 and an Update on Pipeline Programs

Now 20% undervalued

Nasdaq Acknowledges Janux Therapeutics’s Non-Compliance with Listing Rule 5605(b)(1)

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Now 23% undervalued after recent price drop

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.3% to US$27.50

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 85%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics, Inc. Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Consensus revenue estimates increase by 23%

Price target decreased to US$29.67

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Janux Therapeutics, Inc Appoints Brenda Van Vreeswyk as Head of Human Resources

Janux Therapeutics Appoints Winston Kung to Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2000 Growth Index

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics, Inc. Announces Fda Clearance of Investigational New Drug Application for Janx007, A Psma-Tractr for Metastatic Castration-Resistant Prostate Cancer

Janux Therapeutics, Inc. Announces Fda Clearance of Investigational New Drug Application for Janx007, A Psma-Tractr for Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 57%

Janux Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

High number of new directors

Janux Therapeutics, Inc. to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

Consensus forecasts updated

Consensus forecasts updated

Janux Therapeutics, Inc. Appoints Byron Robinson as Chief Strategy Officer

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

High number of new directors

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Insider recently bought US$1m worth of stock

Janux Therapeutics, Inc. has completed an IPO in the amount of $193.8 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera